Differences between males and females in adult sickle cell pain crisis in eastern Saudi Arabia

Annals of Saudi Medicine

Volumn 24, Issue 3, 2004, Pages 179-182

  Udezue, Emmanuel ^a   Girshab, Abdel Moneim ^a  

^a Al Hasa Health Center   (Saudi Arabia)

Author keywords

Gender differences; Pain; Sickle cell disease

Indexed keywords

MORPHINE; OPIATE;

ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG METABOLISM; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; SAUDI ARABIA; SEX DIFFERENCE; SICKLE CELL ANEMIA;

EID: 3142673017     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2004.179     Document Type: Article

References (30)

1. Serjeant GR. The Geography of sickle cell disease: opportunities for understanding its diversity. Ann Saudi Med. 1994;14(3):237-246.
2. Udezue E. A five year experience of a short stay observation unit in Saudi Arabia. Ann Saudi Med. 2003;23(1-2):72-75.
3. Udezue E, Girshab AM. Observations on the management of acute painful crises in adult sickle cell disease. Abstract. International Conference on Sickle Cell Disease: recent advances. Kingdom of Saudi Arabia: Ministry of Health; 2003 Sept 15-18.
4. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, and Klug PP. Mortality in Sickle Cell Disease - Life Expectancy and Risk Factors for Early Death. N Eng J Med. 1994;330(23):1639-1644.
5. Murray N, May A. Painful crises in sickle cell disease - patients' perspectives. BMJ. 1988; 297:452-454.
6. Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999;340(13):1021-1030.
7. Al-Jam'a AH, Al-Dabbous IA. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia. Saudi Med J. 2002;23(3):277-281.
8. Pain and culture. In: Helman CG, ed. Culture health and illness: an introduction for health professionals. 3rd ed. Oxford: Butterworth-Heinemann; 1994:171-193.
9. Westerman MP, Bailey K, Freels S, Schlegel R, Williamson P. Assessment of painful episode frequency in sickle-cell disease. Am J Hematol. 1997;54:183-188.
10. Serjeant GR, Serjeant BE. Cohort studies to understand the natural history of Sickle Cell Disease. Abstract. International Conference on Sickle Cell Disease: recent advances. Kingdom of Saudi Arabia:Ministry of Health; 2003 September 15-18.
11. Schwartz JB. Gender differences in response to drugs: pain medications. J Gend Specif Med. 1999;2(5):28-30.
12. Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs. 1995;50(2):222-239.
13. Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health. 1994;15(8):619-629.
14. Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand. 2003;47(3):241-259.
15. Fillingim RB, Ness TJ. Sex-related influences on pain and analgesic responses. Neurosci Biobehav Rev. 2000;24(4):485-501.
16. Adekile AD, Huisman TH. Level of fetal hemoglobin in children with sickle cell anemia: influence of gender, haplotype and alpha-thalassemia-2 trait. Acta Haematol. 1993;90(1):34-38.
17. Odenheimer DJ, Whitten CF, Rucknagel DA, Sarnaik SA, Sing CF. Stability over time of haematological variables in 197 children with sickle cell anaemia. Am J Med Genet. 1984;18:461-470.
18. Al-Awamy BH, Niazi GA, El Mouzan MI et al. Relationship of hemoglobin F level and alpha thalassemia to severity of sickle cell anemia in the Eastern Province of Saudi Arabia. Ann Trop Med. 1985;5:143-146.
19. Babiker MA, Taha SA. Two different patterns of sickle cell disease in children in Saudi Arabia. Ann Trop Pediatr. 1982;2:179-181.
20. El Hazmi MAF. Haemoglobinopathies, Thalassaemias and Enzymopathies in Saudi Arabia. Saudi Med J. 1992; 13(6):488-499.
21. El Hazmi MA, Jabbar FA, Al Faleh FZ, Al Swailem AM, Warsy AS. The haematological, biochemical and clinical presentation of haemoglobin S in Saudi Arabia. (i) Haematological and clinical expression. Trop Geogr Med. 1987;39(2):157-162.
22. El Hazmi MAF, Warsy AS. On the nature of sickle cell disease in the South Western Province of Saudi Arabia. Act Hematol. 1986;76(4):212-216.
23. Noguchi CT, Rodgers GP, Serjeant GR, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988;318:96-99.
24. Platt OS, Thorington DB, Brambilla DJ et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 1991;325:11-16.
25. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold for level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984; 63: 921-926.
26. de Labry LO, Campion EW, Glynn RJ, Vokonas PS. White blood cell count as a predictor of mortality: results over 18 years from the Normative Aging Study. J Clin Epidemiol. 1990;43:153-157.
27. Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Cillette P et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood. 1994;84(2): 643-649.
28. Al-Suliman A. Acute Chest Syndrome in adult patients with sickle cell anaemia. Abstract. International Conference on Sickle Cell Disease: recent advances. Kingdom of Saudi Arabia: Ministry of Health; 2003 September 15-18.
29. Saxena AK, Panhotra BR, Al-Ghamdi AMA, Sandaram DS. Long term haemodialysis outcome among patients with end-stage sickle cell nephropathy. Abstract. International Conference on Sickle Cell Disease: recent advances. Kingdom of Saudi Arabia: Ministry of Health; 2003 September 15-18.
30. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, Csako G, Waclawiw MA, Panza JA, Cannon RO 3rd. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 2003;107(2):271-278.